medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-12-74-78medsovet-1436Research ArticleВспомогательные репродуктивные технологииAssisted Reproductive TechnologiesПРИМЕНЕНИЕ КОМБИНИРОВАННОГО ПРЕПАРАТА РЕКОМБИНАНТНОГО ФОЛЛИКУЛОСТИМУЛИРУЮЩЕГО ГОРМОНА/ ЛЮТЕИНИЗИРУЮЩЕГО ГОРМОНА В ПРОГРАММАХ ВСПОМОГАТЕЛЬНЫХ РЕПРОДУКТИВНЫХ ТЕХНОЛОГИЙAPPLICATION OF COMBINED DRUG OF RECOMBINANT FOLLICULE-STIMULATING HORMONE/LUTEINIZING HORMONE IN PROGRAMS OF ASSISTED REPRODUCTIVE TECHNOLOGIESСыркашеваА. Г.SyrkashevaA. G.

Кандидат медицинских наук

PhD in medicine

ИбрагимоваЭ. О.IbragimovaE. O.Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова, МоскваРоссияAcademician Kulakov Scientific Obstetrics, Gynecology and Perinatology Center, MoscowRussian Federation2016301220160127478Copyright © Сыркашева А.Г., Ибрагимова Э.О., 20162016Сыркашева А.Г., Ибрагимова Э.О.Syrkasheva A.G., Ibragimova E.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1436

Лечение бесплодия с использованием  вспомогательных  репродуктивных   технологий в подавляющем   большинстве случаев проходит  с использованием  различных  протоколов  стимуляции  яичников  для  получения  оптимального числа ооцитов  и эмбрионов.  Использование  аналогов гонадотропин-рилизинг-гормона в программах ВРТ препятствует  синтезу эндогенных гонадотропинов, что необходимо   для проведения  контролируемой   овариальной  стимуляции, предотвращения преждевременной лютеинизации и получения зрелых ооцитов. Хотя роль лютеинизирующего гормона (ЛГ) в процессе созревания фолликулов и ооцитов не вызывает сомнений, назначение ЛГ-содержащих препаратов для стимуляции яичников следует проводить после индивидуального анализа клинико-анамнестических данных пациентки и данных лабораторного обследования.

Infertility treatment using assisted reproductive technologies in the majority of cases involving the use of various ovarian stimulation protocols to obtain the optimal number of oocytes and embryos.

The use of analogues of gonadotropin-releasing hormone in ART programs prevents the synthesis of endogenous gonadotropins, which is necessary for controlled ovarian stimulation to prevent premature luteinization and obtaining mature oocytes. Although the role of luteinizing hormone (LH) in the process of maturation of follicles and oocytes is not in doubt, the prescription of LH-containing preparations for ovarian stimulation should be performed after individual analysis of clinical and anamnesis data of the patient data and laboratory tests.

бесплодиевспомогательные репродуктивные технологииконтролируемая овариальная стимуляциягонадотропин-рилизинг-гормонinfertilityassisted reproductive technologiescontrolled ovarian stimulationgonadotropin-releasing hormoneReferencesКраснопольская К.В., Назаренко Т.А., Бекетова А.Н., Бадалян Г.В., Черкезов Я.А. Приоритеты при выборе препаратов гонадотропинов для контролируемой стимуляции в программах ЭКО. Проблемы репродукции, 2016, 22(1): 44-9. / Krasnopolskaya K.V., Nazarenko T.A., Beketova A.N., Badalyan G.V., Cherkezov Y.A. Priorities for choice of gonadotropin drugs for controlled stimulation in IVG programs. Reproduction Problems, 2016, 22(1): 44-9.Краснопольская К.В., Назаренко Т.А., Бекетова А.Н., Бадалян Г.В., Черкезов Я.А. Приоритеты при выборе препаратов гонадотропинов для контролируемой стимуляции в программах ЭКО. Проблемы репродукции, 2016, 22(1): 44-9. / Krasnopolskaya K.V., Nazarenko T.A., Beketova A.N., Badalyan G.V., Cherkezov Y.A. Priorities for choice of gonadotropin drugs for controlled stimulation in IVG programs. Reproduction Problems, 2016, 22(1): 44-9.Виноградова Л.В., Мишиева Н.Г., Абубакиров А.Н., Левков Л.А., Мартынова М.В. Гормональные особенности циклов ЭКО, стимулированных человеческим менопаузальным гонадотропином и рекомбинантным ФСГ в протоколах с антагонистом гонадотропин-рилизинг-гормона. Акушерство и гинекология, 2014, 11: 88-95. / Vinogradova L.V., Mishieva N.G., Abubakirov A.N., Levkov L.A., Martynova M.V. Hormonal peculiarities of IVF cycles stimulated by human menopausal gonadotropin and recombinant FSH in protocols with antagonist of gonadotropinreleasing-hormone. Obstetrics and Gynecology, 2014, 11: 88-95.Виноградова Л.В., Мишиева Н.Г., Абубакиров А.Н., Левков Л.А., Мартынова М.В. Гормональные особенности циклов ЭКО, стимулированных человеческим менопаузальным гонадотропином и рекомбинантным ФСГ в протоколах с антагонистом гонадотропин-рилизинг-гормона. Акушерство и гинекология, 2014, 11: 88-95. / Vinogradova L.V., Mishieva N.G., Abubakirov A.N., Levkov L.A., Martynova M.V. Hormonal peculiarities of IVF cycles stimulated by human menopausal gonadotropin and recombinant FSH in protocols with antagonist of gonadotropinreleasing-hormone. Obstetrics and Gynecology, 2014, 11: 88-95.Filicori M, Cognigni G, Pocognoli P, Tabarelli C, Ferlini F, Perri T, et al. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertil Seril, 2003, 80(2): 390-7.Filicori M, Cognigni G, Pocognoli P, Tabarelli C, Ferlini F, Perri T, et al. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertil Seril, 2003, 80(2): 390-7.Hillier S. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod, 1994, 9(2): 188-91.Hillier S. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod, 1994, 9(2): 188-91.Ghaffari E, Arabipoor A, Lankarani N, Etminan Z, Tehraninejad E. Assisted reproductive technique outcomes in hypogonadotropic hypogonadism women. Ann Saudi Med, 2013, 33(3): 235-40.Ghaffari E, Arabipoor A, Lankarani N, Etminan Z, Tehraninejad E. Assisted reproductive technique outcomes in hypogonadotropic hypogonadism women. Ann Saudi Med, 2013, 33(3): 235-40.Белоконь И.П., Уварова Е.В., Киселева И.А., Яворовская К.А., Ходжаева З.С. Реализация репродуктивной функции у женщин с первичным дефицитом эстрогенов гонадного генеза. Акушерство и гинекология, 2012, 4(2): 109-15. / Belokon I.P., Uvarova E.V., Kiseleva I.A., Yavorovskaya I.A., Khodjaeva Z.S. Reproductive function implementation in women with primary deficit of gonad genesis estrogen. Obstetrics and Gynecology, 2012, 4(2): 109-15.Белоконь И.П., Уварова Е.В., Киселева И.А., Яворовская К.А., Ходжаева З.С. Реализация репродуктивной функции у женщин с первичным дефицитом эстрогенов гонадного генеза. Акушерство и гинекология, 2012, 4(2): 109-15. / Belokon I.P., Uvarova E.V., Kiseleva I.A., Yavorovskaya I.A., Khodjaeva Z.S. Reproductive function implementation in women with primary deficit of gonad genesis estrogen. Obstetrics and Gynecology, 2012, 4(2): 109-15.Tesarik J, Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod, 2002, 17(12): 3129-37.Tesarik J, Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod, 2002, 17(12): 3129-37.De Placido G, Mollo A, Alviggi C, Strina I, Varricchio M, Ranieri A, et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod, 2001, 16(9): 1875-9.De Placido G, Mollo A, Alviggi C, Strina I, Varricchio M, Ranieri A, et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod, 2001, 16(9): 1875-9.Asia Pacific Fertility Advisory Group. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online. 2011, 23(1): 81-90.Asia Pacific Fertility Advisory Group. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online. 2011, 23(1): 81-90.Westergaard L, Laursen S, Andersen C. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod, 2000, 15(5): 1003-8.Westergaard L, Laursen S, Andersen C. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod, 2000, 15(5): 1003-8.van Wely M, Kwan I, Burt A, Thomas J, Vail A, Van der Veen F, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review, 2012, 18(2): 5354.van Wely M, Kwan I, Burt A, Thomas J, Vail A, Van der Veen F, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review, 2012, 18(2): 5354.van de Weijer B, Mulders J, Bos E, Verhaert P, van den Hooven H. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online, 2003, 7(5): 547-57.van de Weijer B, Mulders J, Bos E, Verhaert P, van den Hooven H. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online, 2003, 7(5): 547-57.Bosch E. Recombinant human follicular stimulating hormone and recombinant human luteinizing hormone in a 2:1 ratio combination. Pharmacological characteristics and clinical applications. Expert Opin Biol Theor, 2010, 10(6): 1001-9.Bosch E. Recombinant human follicular stimulating hormone and recombinant human luteinizing hormone in a 2:1 ratio combination. Pharmacological characteristics and clinical applications. Expert Opin Biol Theor, 2010, 10(6): 1001-9.Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies. Curr Med Res Opin, 2008, 24(4): 1199-208.Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies. Curr Med Res Opin, 2008, 24(4): 1199-208.Agostinetto R. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment. Reprod Biol Endocrinol, 2009, 7: 48-50.Agostinetto R. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment. Reprod Biol Endocrinol, 2009, 7: 48-50.Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Seril, 2010, 94(6): 2467-9.Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Seril, 2010, 94(6): 2467-9.Bosch E, Labarta E, Crespo J, Simon C, Remoni J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Seril, 2011, 95(3): 1031-6.Bosch E, Labarta E, Crespo J, Simon C, Remoni J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Seril, 2011, 95(3): 1031-6.Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online, 2009, 19(6): 879-87.Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online, 2009, 19(6): 879-87.Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth ? A systematic review and meta-analysis, 2007, 13(5): 445-52.Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth ? A systematic review and meta-analysis, 2007, 13(5): 445-52.Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥ 35 years : a randomized controlled trial. Human Reproduction, 2015, 30(5): 1188-95.Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥ 35 years : a randomized controlled trial. Human Reproduction, 2015, 30(5): 1188-95.Humaidan P, Schertz J, Fischer R. Ef fi cacy and Safety of Pergoveris in Assisted Reproductive Technology – ESPART : rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF / ICSI treatment. BMJ, 2015, 5: 1-6.Humaidan P, Schertz J, Fischer R. Ef fi cacy and Safety of Pergoveris in Assisted Reproductive Technology – ESPART : rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF / ICSI treatment. BMJ, 2015, 5: 1-6.

The authors declare that there are no conflicts of interest present.